U.S. Markets open in 1 hr 28 mins

Amgen Inc. (AMGN)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
169.00-1.07 (-0.63%)
At close: 4:00PM EDT
Full screen
Previous Close170.07
Open169.66
Bid169.33 x 400
Ask170.15 x 100
Day's Range168.76 - 169.94
52 Week Range133.64 - 184.21
Volume1,279,373
Avg. Volume3,037,378
Market Cap123.32B
Beta1.83
PE Ratio (TTM)16.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.70%)
Ex-Dividend Date2017-08-15
1y Target EstN/A
  • MarketWatch15 hours ago

    Amgen's cholesterol drug is cost-effective at $10,000 a year: study

    Amgen Inc.'s cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, according to a new study published in the medical journal JAMA Cardiology. ...

  • Motley Fool2 days ago

    What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?

    Regeneron Pharmaceuticals has launched three new drugs that could kick-start sales growth over the coming years.

  • Barrons.com2 days ago

    Three Biotech Stocks To Buy Amid The (Unsurprising) Dip

    Biotech has underperformed the broader market this month, but Jefferies' Michael Yee writes that that's not really a concern--or a surprise. A little more detail about each: AMGN: key incoming questions around scenarios for upcoming REGN injunction appeals decision where buyside consensus is for majority likelihood AMGN wins with some pot'l for court trying to force a financial settlement w/ large royalty (worth $2-3/share). If AMGN loses, there shouldn't be any change to estimates given consensus has not adjusted any 2018+ PCSK9 numbers for a win though AMGN already won the initial federal injunction decision.